Medicolegal aspects of neoplastic dermatology.
Medical malpractice litigation is rising at an explosive rate in the US and, to a lesser extent, in Canada. The impact of medical malpractice litigation on health care costs and the cost of insurance is dramatic. Certain specialist categories are becoming uninsurable in some parts of the US, while in others, clinicians are retiring early, restricting or changing practice or changing states of residence in consequence of medical malpractice claims and of the cost and availability of insurance. This, in turn, has had the real effect of denying care to patients in some communities in the US. Some 13% of all medical malpractice claims relate to one area of neoplastic dermatopathology, specifically, melanocytic neoplasia. Certain steps can be taken by pathology laboratories to reduce, but never completely eliminate, the risk of medical malpractice claims. In this review, attention is paid to the source of medical malpractice claims and an abbreviated approach to specific strategies for risk management is presented.
Crowson
A Neil
AN
Department of Dermatology, University of Oklahoma and Regional Medical Laboratory, St John Medical Center, Tulsa, OK 74114-4109, USA.
D003880:Dermatology / Q000331:legislation & jurisprudence*; D003951:Diagnostic Errors / Q000331:legislation & jurisprudence / Q000706:statistics & numerical data; D006801:Humans; D008318:Malpractice / Q000331:legislation & jurisprudence; D012878:Skin Neoplasms / Q000175:diagnosis*